Objective: To observe the protection of Gankang tablets on liver injury induced by chemical drugs in animals. Method: Sixty mice were andomly divided into six groups: the normal group

the model group

high-dose Gankang group (19.8 g·kg-1)

middle-dose Gankang group (13.2 g·kg-1)and low-dose Gankang group (6.6 g·kg-1)

Hugang tablet group (150 mg·kg-1). Except for normal group and model group

the other mice were orally administered corresponding drugs once per day for seven days.Then

the treated groups and model group were ip given 0.2%CCl4(20 mL·kg-1) once to produce acute liver injury on fifth day. The Serum was collected after 48 h to detect level of aspartate aminotransferase (AST)

alanine aminotransferase (ALT). Sixty SD rats were randomly divided into six groups: the normal group

the model group

high-dose Gankang group (22.68 g·kg-1)

middle-dose Gankang group (11.34 g·kg-1)and low-dose Gankang group (5.67 g·kg-1)

Hugang group (3.8 g·kg-1). The treated groups were ip 10%CCl4(5 mL·kg-1)once every two week for eight weeks to establish chronic liver injury

whereas the normal were ip given equal volume saline. To observe the hepatic pathological and biochemical indexs changes in rats. Result: Gankang tablets can reduce the level of ALT(47.31±9.37)

(60.14±11.25)U·L-1 and AST(231.67±19.26)

(272.11±15.25)U·L-1of serum in mice which compared with the model group

the high-dose groupor and the middle-dose group showed a significant difference. Gankang tablets can also significantly reduce levels ALT and AST of serumin rats

increasing Albumin (ALB)(40.7±1.5)

(39.6±1.8)g·L-1levels in serum and decreasing tolol bilirubin (TBIL)(9.22±1.90)

(9.34±2.78)μmol·L-1 levels after eight weeks. There was a significant difference compared with model group. Conclusion: Gankang tablets have significant therapeutic effects on CCl4 induced acute liver injury and chronic liver injury.